دورية أكاديمية
Development of small molecule drugs targeting immune checkpoints.
| العنوان: | Development of small molecule drugs targeting immune checkpoints. |
|---|---|
| المؤلفون: | Chen L; Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China., Zhao X; Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China., Liu X; Institute for Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China., Ouyang Y; Acupuncture and Massage College, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China., Xu C; Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China., Shi Y; Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China. |
| المصدر: | Cancer biology & medicine [Cancer Biol Med] 2024 May 09; Vol. 21 (5). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Chinese Anti-Cancer Association Country of Publication: China NLM ID: 101588850 Publication Model: Print Cited Medium: Internet ISSN: 2095-3941 (Print) Linking ISSN: 20953941 NLM ISO Abbreviation: Cancer Biol Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Tianjin] : Chinese Anti-Cancer Association |
| مواضيع طبية MeSH: | Immune Checkpoint Inhibitors*/therapeutic use , Neoplasms*/drug therapy , Neoplasms*/immunology, Humans ; Drug Development ; Immune Checkpoint Proteins/metabolism ; Small Molecule Libraries/pharmacology ; Animals ; Immunotherapy/methods |
| مستخلص: | Immune checkpoint inhibitors (ICIs) are used to relieve and refuel anti-tumor immunity by blocking the interaction, transcription, and translation of co-inhibitory immune checkpoints or degrading co-inhibitory immune checkpoints. Thousands of small molecule drugs or biological materials, especially antibody-based ICIs, are actively being studied and antibodies are currently widely used. Limitations, such as anti-tumor efficacy, poor membrane permeability, and unneglected tolerance issues of antibody-based ICIs, remain evident but are thought to be overcome by small molecule drugs. Recent structural studies have broadened the scope of candidate immune checkpoint molecules, as well as innovative chemical inhibitors. By way of comparison, small molecule drug-based ICIs represent superior oral bioavailability and favorable pharmacokinetic features. Several ongoing clinical trials are exploring the synergetic effect of ICIs and other therapeutic strategies based on multiple ICI functions, including immune regulation, anti-angiogenesis, and cell cycle regulation. In this review we summarized the current progression of small molecule ICIs and the mechanism underlying immune checkpoint proteins, which will lay the foundation for further exploration. Competing Interests: No potential conflicts of interest are disclosed. (Copyright: © 2024, The Authors.) |
| References: | Nat Med. 2019 Aug;25(8):1243-1250. (PMID: 31332390) Front Oncol. 2018 Sep 11;8:370. (PMID: 30254983) Immunity. 2016 May 17;44(5):989-1004. (PMID: 27192565) Cancer Biol Med. 2023 Dec 7;21(3):. (PMID: 38062861) Front Pharmacol. 2021 Jun 21;12:677120. (PMID: 34234673) J Med Chem. 2023 Aug 10;66(15):10364-10380. (PMID: 37480153) ACS Med Chem Lett. 2022 Aug 16;13(9):1459-1467. (PMID: 36105338) Cancer Cell. 2023 Feb 13;41(2):272-287.e9. (PMID: 36706761) Eur J Cancer. 2021 May;148:76-91. (PMID: 33740500) Invest New Drugs. 2020 Dec;38(6):1784-1795. (PMID: 32436060) Oral Oncol. 2016 Jun;57:54-60. (PMID: 27208845) Mol Oncol. 2012 Apr;6(2):155-76. (PMID: 22440008) Int Immunol. 2007 Jul;19(7):813-24. (PMID: 17606980) Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697. (PMID: 30635425) Bioorg Chem. 2023 Dec;141:106894. (PMID: 37776682) Immunol Rev. 2017 Mar;276(1):5-8. (PMID: 28258698) Nat Commun. 2021 Sep 1;12(1):5218. (PMID: 34471125) PLoS One. 2020 Mar 26;15(3):e0228339. (PMID: 32214351) PLoS One. 2020 Apr 2;15(4):e0226661. (PMID: 32240171) Nat Rev Drug Discov. 2019 Jun;18(6):463-477. (PMID: 30976107) Biomed Res. 2019;40(6):243-250. (PMID: 31839668) Nat Commun. 2021 Feb 22;12(1):1222. (PMID: 33619272) Cancer Lett. 2023 Jun 28;564:216205. (PMID: 37146936) Front Immunol. 2023 Mar 07;14:1104753. (PMID: 36960054) J Med Chem. 2023 May 25;66(10):6811-6835. (PMID: 37159395) Eur J Med Chem. 2022 Feb 5;229:114047. (PMID: 34915428) Clin Cancer Res. 2018 Apr 1;24(7):1562-1573. (PMID: 29203588) Cell Rep Med. 2024 Feb 20;5(2):101357. (PMID: 38237597) J Med Chem. 2023 Aug 24;66(16):11464-11475. (PMID: 37566998) Transl Oncol. 2019 Apr;12(4):626-632. (PMID: 30738349) Adv Sci (Weinh). 2023 Oct;10(28):e2302422. (PMID: 37544896) J Immunother Cancer. 2022 Jun;10(6):. (PMID: 35728870) Pharmaceutics. 2021 Apr 21;13(5):. (PMID: 33919384) Structure. 2015 Dec 1;23(12):2341-2348. (PMID: 26602187) Cancer Biol Med. 2023 May 13;20(6):. (PMID: 37184030) ACS Omega. 2023 Sep 03;8(37):33242-33254. (PMID: 37744828) Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. (PMID: 27935336) Immunity. 2018 Mar 20;48(3):434-452. (PMID: 29562194) Pestic Biochem Physiol. 2020 Sep;168:104624. (PMID: 32711764) Nat Rev Cancer. 2021 Oct;21(10):638-654. (PMID: 34131295) Chem Soc Rev. 2022 Jul 4;51(13):5498-5517. (PMID: 35723413) J Am Chem Soc. 2020 Sep 23;142(38):16194-16198. (PMID: 32894020) Drug Dev Res. 2022 Feb;83(1):176-183. (PMID: 34309063) Commun Biol. 2021 Jun 8;4(1):699. (PMID: 34103659) Trends Immunol. 2018 Mar;39(3):173-184. (PMID: 29336991) J Immunother Cancer. 2018 Jun 20;6(1):61. (PMID: 29921320) Nat Chem Biol. 2012 Nov;8(11):890-6. (PMID: 23023262) J Exp Med. 2011 Mar 14;208(3):577-92. (PMID: 21383057) Nat Rev Drug Discov. 2023 Nov;22(11):895-916. (PMID: 37697042) PLoS One. 2019 Jul 5;14(7):e0218897. (PMID: 31276567) Mod Pathol. 2017 Dec;30(12):1666-1676. (PMID: 28776578) Molecules. 2019 Aug 01;24(15):. (PMID: 31374878) Comput Biol Chem. 2023 Feb;102:107804. (PMID: 36610303) Blood. 2010 Apr 29;115(17):3520-30. (PMID: 20197554) Lancet Oncol. 2019 Aug;20(8):1083-1097. (PMID: 31221619) Oncotarget. 2016 May 24;7(21):30323-35. (PMID: 27083005) Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. (PMID: 30770348) Nat Chem Biol. 2019 Jan;15(1):42-50. (PMID: 30397328) Nat Med. 2017 May;23(5):551-555. (PMID: 28346412) J Med Chem. 2021 Oct 14;64(19):14757-14772. (PMID: 34597046) Annu Rev Immunol. 2016 May 20;34:539-73. (PMID: 26927206) J Transl Med. 2023 Jul 14;21(1):467. (PMID: 37452307) Nat Commun. 2023 Nov 11;14(1):7306. (PMID: 37951973) Bioorg Chem. 2021 Jun;111:104833. (PMID: 33839580) Sci Transl Med. 2023 Nov 15;15(722):eadg6752. (PMID: 37967204) Immunity. 2020 May 19;52(5):742-752. (PMID: 32433947) J Immunother Cancer. 2023 Jun;11(6):. (PMID: 37344099) J Immunother. 2021 Sep 1;44(7):264-275. (PMID: 33928928) Sci Adv. 2023 Apr 7;9(14):eade9944. (PMID: 37027467) Invest New Drugs. 2016 Jun;34(3):371-7. (PMID: 26841903) Sci Rep. 2019 Aug 27;9(1):12392. (PMID: 31455818) Adv Mater. 2023 Feb;35(6):e2208553. (PMID: 36427459) J Clin Oncol. 2019 Apr 20;37(12):946-953. (PMID: 30811285) J Med Chem. 2023 Mar 23;66(6):3896-3916. (PMID: 36856685) Cancer Immunol Immunother. 2005 Apr;54(4):307-14. (PMID: 15599732) Mol Ther Nucleic Acids. 2023 Feb 18;31:691-702. (PMID: 36923950) Nat Rev Cancer. 2006 Sep;6(9):714-27. (PMID: 16929325) Acta Pharmacol Sin. 2021 Jan;42(1):1-9. (PMID: 32152439) Pharmacol Res. 2018 Sep;135:166-180. (PMID: 30103001) J Clin Invest. 2014 May;124(5):1966-75. (PMID: 24743150) Cell Res. 2020 Aug;30(8):660-669. (PMID: 32467592) J Hematol Oncol. 2020 Jun 29;13(1):83. (PMID: 32600443) J Exp Med. 2001 Apr 2;193(7):855-62. (PMID: 11283158) Int Immunopharmacol. 2023 May;118:109993. (PMID: 36931170) Acta Pharmacol Sin. 2023 Oct;44(10):2103-2112. (PMID: 37193754) Acta Pharm Sin B. 2022 Jun;12(6):2845-2858. (PMID: 35755282) Mol Divers. 2023 Aug;27(4):1633-1644. (PMID: 36006501) J Control Release. 2021 Apr 10;332:194-209. (PMID: 33631225) Comput Struct Biotechnol J. 2021 Oct 01;19:5494-5503. (PMID: 34712395) Front Immunol. 2023 May 02;14:1145028. (PMID: 37205112) Mol Ther. 2018 Dec 5;26(12):2738-2750. (PMID: 30301668) Nat Commun. 2023 Jul 14;14(1):4217. (PMID: 37452028) J Cell Mol Med. 2019 Sep;23(9):5994-6004. (PMID: 31273952) Life (Basel). 2022 Aug 12;12(8):. (PMID: 36013403) Bioorg Chem. 2022 Jun;123:105769. (PMID: 35405572) Drug Discov Today. 2020 Oct;25(10):1807-1821. (PMID: 32801051) Front Chem. 2023 Oct 20;11:1292869. (PMID: 37927570) Nat Med. 2016 Feb;22(2):128-34. (PMID: 26845405) Mol Cancer. 2022 Jan 21;21(1):28. (PMID: 35062949) Annu Rev Pathol. 2021 Jan 24;16:223-249. (PMID: 33197221) Cancer Discov. 2022 Jun 2;12(6):1482-1499. (PMID: 35254416) J Immunother Cancer. 2020 Oct;8(2):. (PMID: 33020240) Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):551-559. (PMID: 36646388) J Biol Chem. 2014 Apr 4;289(14):10024-8. (PMID: 24550402) Nat Rev Drug Discov. 2016 Aug;15(8):533-50. (PMID: 27050677) Front Immunol. 2020 Jan 31;10:3135. (PMID: 32082304) Cell Chem Biol. 2020 Sep 17;27(9):1181-1191.e7. (PMID: 32640189) Nat Med. 2019 Feb;25(2):301-311. (PMID: 30643286) Biofactors. 2022 Sep;48(5):1137-1144. (PMID: 35533068) Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7. (PMID: 25964334) Cancer Biol Med. 2023 Mar 24;20(3):. (PMID: 36971124) Future Oncol. 2020 Jan;16(2):4359-4368. (PMID: 31823654) Drug Discov Today. 2021 Feb;26(2):561-568. (PMID: 33197622) |
| معلومات مُعتمدة: | 82203539 National Natural Science Foundation of China; 92259102 National Natural Science Foundation of China; 2023YFSY0043 Provincial Cooperation Project of Science and Technology Department of Sichuan Province; 2023YFC3402100 National Key Research and Development Program of China |
| فهرسة مساهمة: | Keywords: CD47; Immune checkpoints; programmed death protein 1; signal-regulatory protein α; small molecule drugs |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) 0 (Immune Checkpoint Proteins) 0 (Small Molecule Libraries) |
| تواريخ الأحداث: | Date Created: 20240510 Date Completed: 20240528 Latest Revision: 20240530 |
| رمز التحديث: | 20240530 |
| مُعرف محوري في PubMed: | PMC11131045 |
| DOI: | 10.20892/j.issn.2095-3941.2024.0034 |
| PMID: | 38727005 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2095-3941 |
|---|---|
| DOI: | 10.20892/j.issn.2095-3941.2024.0034 |